8-K: Aquestive Therapeutics Receives FDA Approval for Libervant in Pediatric Patients and Updates Anaphylm Program

Aquestive Therapeutics announced FDA approval for Libervant (diazepam) Buccal Film for treating seizure clusters in children aged 2 to 5 and provided an update on the Anaphylm (epinephrine) Sublingual Film development program.

Summary

• Aquestive Therapeutics has received FDA approval for Libervant (diazepam) Buccal Film for the acute treatment of seizure clusters in patients aged 2 to 5 years.
• Libervant is the first and only FDA-approved orally administered rescue product for this specific patient group.
• The company has made Libervant available in 5mg, 7.5mg, 10mg, 12.5mg, and 15mg dosages for patients between 2 and 5 years of age.
• Aquestive's Anaphylm (epinephrine) Sublingual Film clinical development program is on track, with an NDA submission planned for the end of 2024.
• In 2023, over 55,000 prescriptions were filled for patients between the ages of 2 and 5, with a 10.8% increase over the previous year and an average increase of 9.3% over the last three years.
• Over 90% of filled prescriptions in 2023 for this patient population were for diazepam rectal gel, indicating a potential market for Libervant as an alternative.
• The company will host a conference call on April 29, 2024, to discuss the approval and provide further updates.

Sentiment

Score: 8

Explanation: The document is highly positive due to the FDA approval of Libervant and the progress of the Anaphylm program. While there are risks mentioned, the overall tone is optimistic and forward-looking.

Positives

• FDA approval of Libervant provides a new treatment option for young children experiencing seizure clusters.
• Libervant is an orally administered film, offering a more convenient alternative to rectal gel.
• The Anaphylm program is progressing as planned, with a target NDA submission by the end of 2024.
• The company has a track record of four FDA approvals since 2018.
• The company is expanding its distribution capabilities for Libervant.

Negatives

• The company faces potential litigation risks related to overcoming orphan drug exclusivity for pediatric epilepsy patients.
• There are risks associated with the commercialization of a new product, including market acceptance and regulatory limitations.
• The company faces risks related to manufacturing capacity to meet demand for Libervant.
• Suboxone, a significant revenue source, is a sunsetting product, posing a risk to future revenue.

Risks

• There are risks associated with the distribution of Libervant, including delays and changes in timing and cost.
• The company faces potential litigation related to orphan drug exclusivity.
• There are risks associated with the development of Anaphylm, including delays and changes in timing and cost.
• The company may not generate sufficient data for FDA approval of Anaphylm.
• The FDA may require additional clinical studies for Anaphylm approval.
• There is a risk of delays in or failure to receive FDA approval for Anaphylm.
• The company faces risks related to market acceptance of Libervant and Anaphylm.
• There is a risk of insufficient capital and cash resources to fund commercialization and development activities.
• The company faces risks related to intellectual property rights and infringement claims.
• General economic, political, and market conditions could impact the company's performance.

Future Outlook

The company plans to expand distribution capabilities for Libervant and aims to submit an NDA for Anaphylm by the end of 2024. They will provide further updates on Anaphylm during the Q1 2024 earnings call.

Management Comments

• Daniel Barber, Chief Executive Officer of Aquestive, stated that they are thrilled to have received FDA approval for Libervant in patients between the ages of two and five.
• Daniel Barber also mentioned that patients have been waiting years for Libervant, the first and only FDA approved orally-administered rescue product for the treatment of seizure clusters.
• Daniel Barber stated that their first priority is to provide and maintain availability of Libervant to the intended patient population.
• Michael Rogawski, M.D., Ph.D, stated that Libervant provides a new way to deliver diazepam for the treatment of acute repetitive seizure emergencies in children aged two to five.

Industry Context

The approval of Libervant addresses an unmet need for a convenient, orally administered treatment for seizure clusters in young children, offering an alternative to existing rectal gel and nasal spray products. The Anaphylm program targets a significant market for epinephrine delivery, potentially competing with existing auto-injector devices.

Comparison to Industry Standards

• Libervant is positioned as a novel alternative to existing diazepam rectal gel, which currently holds over 90% of the market share for this patient population, suggesting a significant opportunity for market penetration.
• The company is competing with companies that produce epinephrine auto-injectors, such as Mylan (now Viatris) with EpiPen, and other companies developing alternative delivery methods for epinephrine.
• The company's focus on film-based drug delivery technology is a differentiator in the pharmaceutical industry, offering potential advantages in terms of ease of use and patient compliance compared to traditional methods.

Stakeholder Impact

• Shareholders will likely react positively to the FDA approval and progress of the Anaphylm program.
• Patients and their families will benefit from the availability of a new, convenient treatment option for seizure clusters.
• Employees may experience increased workload and opportunities due to the commercialization of Libervant and development of Anaphylm.
• The company's suppliers and partners may see increased business opportunities.

Next Steps

• Aquestive will expand its distribution capabilities for Libervant.
• The company will continue clinical studies for Anaphylm.
• Aquestive plans to submit an NDA for Anaphylm by the end of 2024.
• The company will provide a more detailed update on Anaphylm at its upcoming first quarter 2024 earnings call on May 8, 2024.

Key Dates

Keywords

Libervant, Anaphylm, FDA approval, seizure clusters, epinephrine, diazepam, buccal film, sublingual film, pediatric epilepsy, NDA submission